• Search
  • Advanced Search

Editorial

March 31, 2025


Editorial for JUO 2025 Vol. 23 No. 1 - Highlights of This Issue’s Papers and the JUO Editors’ Pick
Cheol Kwak
J Urol Oncol. 2025;23(1):1-3.

Invited Review

March 31, 2025


Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review
Gabriela M. Diaz, Peter S. Palencia, Michael S. Leapman
J Urol Oncol. 2025;23(1):4-13.

Precision oncology offers a transformative approach to managing localized prostate cancer (PCa) by tailoring interventions to the biological characteristics of the disease. This strategy addresses critical challenges such as overdiagnosis,...

Original Article

March 31, 2025


The Clinical Impact of Depression and Anxiety on Complications After Prostate Cancer Treatment: A Retrospective Cohort Study
Elliott J. Druten, Will P. Hoover, Jacob Bardell, et al.
J Urol Oncol. 2025;23(1):14-19.

Purpose: This large retrospective study aims to better understand the relationship of depression and anxiety with posttreatment complications in prostate cancer patients, specifically erectile dysfunction (ED) and urinary incontinence. Materials and...

Original Article

March 31, 2025


A Urologist’s Perspective: Initial Experiences With SpaceOAR Hydrogel Insertion for Prostate Cancer Patients
Hyunho Han, Ik Jae Lee, Woong Sub Koom, et al.
J Urol Oncol. 2025;23(1):20-29.

Purpose: To evaluate the placement accuracy and learning curve of SpaceOAR hydrogel and gold fiducial marker insertion in Korean prostate cancer patients undergoing carbon ion radiotherapy (CIRT), performed by a...

Original Article

March 31, 2025


Prognostic Impact of Seminal Vesicle Mucosal Invasion in pT3b Prostate Cancer Following Radical Prostatectomy
Hyun Jung Lee, Won Hoon Song, Seung Soo Lee, et al.
J Urol Oncol. 2025;23(1):30-37.

Purpose: The extent of seminal vesicle invasion (SVI) in prostate cancer can be classified into muscle layer invasion (SVI-muscle) and mucosal layer invasion (SVI-mucosa). This study aimed to evaluate the...

Invited Review

March 31, 2025


Selection of Optimal Neoadjuvant Therapy Before Cytoreductive Nephrectomy and Its Biomarker in Renal Cell Carcinoma
Renpei Kato
J Urol Oncol. 2025;23(1):38-46.

Cytoreductive nephrectomy (CN) has been a pivotal consideration in the treatment of metastatic renal cell carcinoma, with its role evolving significantly in the era of immuno-oncology (IO) therapies. This review...

Original Article

March 31, 2025


Predicting Oncological and Functional Outcomes by Nephrectomy Type for T1 Renal Tumors Using Machine Learning Models
Dongrul Shin, Maisy Song, Jungyo Suh, et al.
J Urol Oncol. 2025;23(1):47-53.

Purpose: Determining the optimal surgical approach for patients with T1 renal tumors requires balancing long-term oncological and renal functional outcomes. Using machine learning algorithms, we aimed to develop a model...

Original Article

March 31, 2025


Prognostic Implications of Serum Carbonic Anhydrase IX in Clear Cell Renal Cell Carcinoma
Mónica Sanz del Pozo, Cristina Plaza Alonso, Álvaro Linacero Gracia, et al.
J Urol Oncol. 2025;23(1):54-62.

Purpose: The present study aimed at determining the expression of carbonic anhydrase IX (CAIX) in tissue and serum of patients with clear cell renal cell carcinoma (ccRCC) and its relationship...

Invited Review

March 31, 2025


A Review of Emerging Neoadjuvant Intravesical Strategies to Enhance Systemic Immune Checkpoint Blockade in Patients With Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Through the Induction of Immunogenic Cell Death and Activation of Tertiary Lymphoid Structure formation
Hye Won Lee, Hyun Hwan Sung
J Urol Oncol. 2025;23(1):63-78.
Patients diagnosed with muscle-invasive bladder cancer (MIBC) frequently exhibit a high incidence of micrometastatic disease. The current standard of care for localized MIBC involves cisplatin-based neoadjuvant chemotherapy followed by radical...

Original Article

March 31, 2025


Impact of Extended Lymph Node Dissection on Survival Outcomes in Patients With Bladder Cancer and Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study
Jiwoong Yu, Wook Nam, Kyung Hwan Kim, et al.
J Urol Oncol. 2025;23(1):79-87.
Purpose: To evaluate whether extended pelvic lymph node dissection (PLND) improves survival outcomes compared with standard PLND in patients with bladder cancer (BCa) undergoing radical cystectomy (RC), and to assess...

Original Article

March 31, 2025


Gender and Menopause Impact on Recurrence and Cancer-Specific Mortality in Bladder Cancer After Radical Cystectomy: A Retrospective Cohort Study
Jee Soo Park, Won Sik Jang, Jieun Heo, et al.
J Urol Oncol. 2025;23(1):88-93.
Purpose: Although bladder cancer occurs three to 4 times more frequently in men than in women, the relative number of deaths compared to incidence is higher in women, suggesting that...
Current Issue
Volume 23(1); Mar 2025
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Sang Heon Han, Hyeong Dong Yuk
J Urol Oncol. 2023;21(1):32-44.

Original Article

Mar 31, 2023

The Landscape of Epidemiology in Urologic Cancers
Complex Epidemiology of Prostate Cancer in Asian Countries
Kagenori Ito, Takahiro Kimura
J Urol Oncol. 2023;21(1):5-13.

Review Article

Mar 31, 2023
Prostate-Specific Antigen-Based Prostate Cancer Screening: One for All or Individualized for Each Race? – A Narrative Review
Chang Wook Jeong
J Urol Oncol. 2024;22(1):4-10.

Invited Review

Mar 31, 2024

Prostate Cancer
Health Equity Research Outcomes and Improvement Consortium Prostate Cancer Health Precision Africa1K: Closing the Health Equity Gap Through Rural Community Inclusion
Vanessa M. Hayes, Sean M. Patrick, Joyce Shirinde, et al.
J Urol Oncol. 2024;22(2):144-149.

Invited Review

Jul 31, 2024

Prostate Cancer
A Cost-Benefit Comparison of Biparametric Magnetic Resonance Imaging Versus Conventional Prostate Cancer Screening
Jung Sik Huh, Kyung Kgi Park
J Urol Oncol. 2023;21(2):121-127.

Original Article

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Sang Hun Song, Jong Jin Oh
J Urol Oncol. 2023;21(2):154-164.

Invited Review

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Global Renal Cell Carcinoma Research Trends Over 30 Years: A PRISMA-Compliant Bibliometric Analysis
Jung Hoon Kim, Ji Woong Hwang
J Urol Oncol. 2024;22(1):42-51.

Original Article

Mar 31, 2024

Kidney Cancer
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
Byung Kwan Park
J Urol Oncol. 2023;21(2):106-111.

Invited Review

Jul 31, 2023

mpMRI in the Management of Prostate Cancer: Role, Limitation, and Cost-Effectiveness
Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer
Yongsoo Jo, Hyeong Dong Yuk
J Urol Oncol. 2024;22(3):256-267.

Invited Review

Nov 30, 2024

Bladder Cancer
Current Update on Prostate Cancer Immunotherapy
Juliana E. Kim, Kunwoo Lee, Isaac Yi Kim
J Urol Oncol. 2023;21(1):14-22.

Review Article

Mar 31, 2023
Bladder Cancer in South Korea: Analysis of Trends and Risk Factors of Bladder Cancer in South Korea Using a Nationwide Database
Sangjun Yoo, Kyung-Do Han, Kwang Taek Kim, et al.
J Urol Oncol. 2023;21(1):45-52.

Original Article

Mar 31, 2023
The Predictive Value of the Preoperative Systemic Inflammatory Response Indices in Non–Organ-Confined Disease in Upper Urinary Tract Urothelial Carcinoma
Sung Kyung Choi, Chan Hoon Gwak, Jungyo Suh, et al.
J Urol Oncol. 2023;21(2):174-180.

Original Article

Jul 31, 2023

Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Invited Review

Nov 30, 2023

Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Invited Review

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.Correction in: 2024;22(2):183

Original Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
Chung Un Lee, Wan Song, Minyong Kang, et al.
J Urol Oncol. 2023;21(3):241-248.

Topic Article

Nov 30, 2023

Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma
Sung Han Kim, Ilma S. Savul, Seth P. Lerner
J Urol Oncol. 2024;22(1):68-77.

Invited Review

Mar 31, 2024

Bladder Cancer
Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
Minseok Suh, Gi Jeong Cheon
J Urol Oncol. 2024;22(1):11-20.

Invited Review

Mar 31, 2024

Prostate Cancer
Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
Joohyun Hong, Ghee Young Kwon, Minyong Kang, et al.
J Urol Oncol. 2024;22(1):59-67.

Original Article

Mar 31, 2024

Kidney Cancer
Targeted Therapy Following Metastasectomy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Hui Mo Gu, Seung Il Jung, Dongdeuk Kwon, et al.
J Urol Oncol. 2024;22(1):34-41.

Systemic Review and Meta-analysis

Mar 31, 2024

Kidney Cancer
Robot-Assisted Radical Nephrectomy With Inferior Vena Cava Thrombectomy: A Narrative Review With Step-by-Step Procedures
Seokhwan Bang, Sung-Hoo Hong
J Urol Oncol. 2024;22(2):105-114.

Invited Review

Jul 31, 2024

Renal Cell Carcinoma
Pathologic Diagnosis of Renal Cell Carcinoma in the Era of the 2022 World Health Organization Classification: Key Points for Clinicians
Bokyung Ahn, Jinahn Jeong, Yong Il Lee, et al.
J Urol Oncol. 2024;22(2):115-127.

Invited Review

Jul 31, 2024

Renal Cell Carcinoma
Early Experience of the Single-Port Robotic Transvesical Radical Prostatectomy: Case Series
Jae Hoon Chung, Hwanik Kim, Woo Jin Bang, et al.
J Urol Oncol. 2024;22(3):188-195.

Original Article

Nov 30, 2024

Prostate Cancer
The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
Jong Ho Park, Jong Jin Oh
J Urol Oncol. 2024;22(3):246-255.

Invited Review

Nov 30, 2024

Bladder Cancer
Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review
Gabriela M. Diaz, Peter S. Palencia, Michael S. Leapman
J Urol Oncol. 2025;23(1):4-13.

Invited Review

Mar 31, 2025

Prostate Cancer
The Current State and Future of Plasma Cell-Free DNA Analysis in Urologic Malignancies
Shusuke Akamatsu, Kei Mizuno, Takayuki Sumiyoshi, et al.
J Urol Oncol. 2023;21(1):23-31.

Review Article

Mar 31, 2023
Contemporary Management of Small Renal Masses by Urologic Oncologists: A 2022 Korean Renal Cancer Study Group Practice Pattern Survey
Joongwon Choi, Cheryn Song, Jungyo Suh, et al.
J Urol Oncol. 2023;21(1):59-69.

Original Article

Mar 31, 2023
Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
Dong Gyun Kim, Ji Eun Heo, Kang Su Cho, et al.
J Urol Oncol. 2023;21(1):70-78.

Original Article

Mar 31, 2023
The Prognostic Significance of Body Mass Index in Patients Undergoing Nephrectomy for Nonmetastatic Renal Cell Carcinoma
Hee Jae Yoo, Sun Il Kim, Se Joong Kim, et al.
J Urol Oncol. 2023;21(1):88-94.

Original Article

Mar 31, 2023

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org
Korean Urological Oncology Society
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-704-8574, E-mail: leeseh@yuhs.ac

Copyright © The Korean Urological Oncology Society.

Developed in M2PI